Ticlopidine was not better than aspirin for preventing recurrent stroke in African-Americans with noncardioembolic ischemic stroke.

P a t i e n t s 1809 African-American patients 29 to 85 years of age (mean age 61 y, 53% women), who had noncardioembolic ischemic stroke onset ≥ 7 but not ≥ 90 days, cranial computed tomography or magnetic resonance imaging of the brain consistent with the entry cerebral infarction, measurable neurologic deficit that correlates with entry cerebral infarction, and availability for follow-up in an outpatient treatment program. Exclusion criteria included transient ischemic attack, subarachnoid hemorrhage, cardiac source embolism, iatrogenic stroke, nonatherosclerotic stroke, postoperative stroke occurring within 30 days of operation, and carotid endarterectomy as primary treatment measure for entry cerebral infarction. All patients were included in the analysis.